News
-
-
-
-
PRESS RELEASE
New to the Street to Broadcast on Bloomberg Saturday, September 28th at 6:30 PM EST - Featuring LightPath Technologies' Groundbreaking Advances in Optics
New to The Street to feature Banzai International's CEO on debt restructuring and Innovative MedTech's CEO on elder care solutions, along with other industry updates. Showcasing advancements in optics and cybersecurity protection -
-
PRESS RELEASE
Spectral Capital (FCCN) Announces $15 Million Private Placement Memorandum Agreement with Spark Market
Spectral Capital Corporation partners with Spark Market to raise $15 million for Quantum Bridge Program & Green Micro Data Center Network expansion, promoting accessibility to high-impact investments and sustainability -
-
PRESS RELEASE
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
US FDA approves Dupixent as the first-ever biologic medicine for COPD, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. Dupixent is now leading in new-to-brand prescriptions for FDA-approved indications -
PRESS RELEASE
Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
La FDA approuve Dupixent comme premier médicament biologique pour la BPCO aux États-Unis, offrant un nouveau traitement aux patients inadéquatement contrôlés. Résultats positifs des études BOREAS et NOTUS -
REGULATED PRESS RELEASE
i2S : Rapport Financier Semestriel 2024 - Annule et remplace